# Shares of Zymeworks and Jazz Pharmaceuticals climbed after the companies released what they called positive topline results from a late-stage trial.

*biotech · news · 2025-11-17 · MarketScreener*

## Key points

- Zymeworks and Jazz Pharmaceuticals reported positive topline results from a late-stage zanidatamab-hrii trial.
- Zanidatamab-hrii combined with chemotherapy showed a safety profile consistent with known agent profiles.
- The companies plan to submit a supplemental biologics license application for first-line use in 2026.
- Zanidatamab-hrii is currently approved as Ziihera for second-line biliary tract cancer in multiple regions.
- BeOne Medicines is collaborating in the development and commercialization of zanidatamab-hrii.

**Companies:** Jazz Pharmaceuticals, Zymeworks, BeOne Medicines
**Countries:** United States, Europe, China

[Read the full story on MarketScreener](https://www.marketscreener.com/news/zymeworks-jazz-pharmaceuticals-shares-rise-following-positive-phase-3-results-for-cancer-treatment-ce7d5edad88ff525)

---

Canonical: https://newsio.io/n/1cee3a9f-ad75-4c8e-bf23-21e50a43a80f/shares-of-zymeworks-and-jazz-pharmaceuticals-climbed-after-the-companies-release
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works